J Drugs Dermatol. 2026 Aug 1;25(8):737-741. doi: 10.36849/JDD.10110.
ABSTRACT
BACKGROUND: Eczema is a prevalent, chronic skin condition that affects up to 10% of adults globally and is characterized by recurrent eczematous lesions. Intense itch is often the most burdensome symptom, leading to sleep disturbances and declining quality of life. Additionally, itch–scratch cycles perpetuate skin barrier damage and inflammation. Regular skincare with moisturizers is recognized as a cornerstone of eczema management.
OBJECTIVES: This study evaluated the itch relief and safety of Cetaphil® Restoraderm Eczema Soothing Moisturizer (eczema moisturizer) and Cetaphil® Restoraderm Eczema Rapid Relief Cream (eczema cream; Galderma Laboratories, LP, Fort Worth, TX) in individuals with eczema-prone skin.
METHODS: Thirty-three participants with bilateral eczema-prone skin and mild-to-moderate itch were randomized to blinded, split-body application of the products. Evaluations over 24 hours included time to onset of itch relief, grading of itch severity (11-point itch severity numerical rating scale [NRS]), self-assessment questionnaire (4-point structured scale), and safety assessments.
RESULTS: The eczema moisturizer and the eczema cream provided rapid itch relief after a single application, with mean times to itch relief of 38 seconds and 43 seconds, respectively. Both treatments significantly reduced itch severity from baseline by 98% to 99% at 24 hours (eczema moisturizer mean NRS: 0.03; P<0.0001; eczema cream mean NRS: 0.09; P<0.0001). Self-assessment questionnaires demonstrated high participant satisfaction with both products after a single application.
CONCLUSION: Single applications of eczema moisturizer and eczema cream were well tolerated, well perceived by participants, and provided rapid and sustained itch relief over 24 hours.  .
PMID:42555074 | DOI:10.36849/JDD.10110
